Significantly improving treatment outcomes for patients with cancer by applying phosphoramidite chemistry technology to transform some of the most widely prescribed chemotherapy agents into more effective and safer medicines. (NASDAQ: NCNA)
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 29.11.2011 | Series A | $10.53M | - |
Mentions in press and media 4
| Date | Title | Description |
| 28.09.2017 | Term Sheet — Thursday, September 28 | DIAL UP THE DRAMA
Good morning, Term Sheet readers!
Paid Content You can't secure what you can't see From ExtraHop
BITCOIN SOUND OFF: The Wolf of Wall Street has spoken. Jordan Belfort, the former stockbroker who pled guilty to fraud, calle... |
| 19.09.2017 | Term Sheet — Tuesday, September 19 | VCs VERSUS ICOs
Companies have raised more than $1.7 billion through initial coin offerings this year, surpassing early-stage VC funding for Internet companies. It’s easy to see why an ICO is appealing to tech founders (No due diligence! LO... |
| 05.09.2017 | Term Sheet — Tuesday, September 5 | CATCH UP
Good morning, Term Sheet readers.
Paid Content What you need to know about growing cyberattacks From ExtraHop
SQUEEZED OUT: On Friday, we bid farewell to Juicero, our favorite juicer company to make fun of on Twitter. After raising... |
| 29.11.2011 | NuCana BioMed Closes £6.74M Series A Venture Funding | NuCana BioMed, an Edinburgh UK-based biopharmaceutical company focused on anti-cancer therapies, has closed a £6.74m (approximately $10.4m) Series A venture funding.
The round was led by Sofinnova Partners, with participation from Morningsi... |
Reviews 0
